drugset / Trial / NCT00805818
Study of NNZ-2566 in Patients With Traumatic Brain Injury
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
Timeline
- Start
- 2010-04
- Primary completion
- 2016-01
- Completion
- 2016-01
Publications
- Lee JW. The EEG Ictal-Interictal Continuum-A Metabolic Roar But a Whimper of a Functional Outcome. Epilepsy Curr. 2019 Jul-Aug;19(4):234-236. doi: 10.1177/1535759719855968. Epub 2019 Jun 14.
- Lee H, Mizrahi MA, Hartings JA, Sharma S, Pahren L, Ngwenya LB, Moseley BD, Privitera M, Tortella FC, Foreman B. Continuous Electroencephalography After Moderate to Severe Traumatic Brain Injury. Crit Care Med. 2019 Apr;47(4):574-582. doi: 10.1097/CCM.0000000000003639.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trofinetide | Peptide | 1 mg/kg | Intravenous |
| Subject | Trofinetide | Peptide | 3 mg/kg | Intravenous |
| Subject | Trofinetide | Peptide | 6 mg/kg | Intravenous |